Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.27 AUD | +3.15% |
|
+6.35% | -14.82% |
05-28 | Transcript : Neuren Pharmaceuticals Limited - Shareholder/Analyst Call | |
05-27 | Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.82% | 1.81B | |
+55.32% | 815B | |
+44.05% | 641B | |
-6.75% | 352B | |
+13.56% | 314B | |
+10.68% | 303B | |
+16.57% | 242B | |
+2.04% | 224B | |
+13.31% | 218B | |
+8.48% | 168B |
- Stock Market
- Equities
- NEU Stock
- News Neuren Pharmaceuticals Limited
- Neuren Pharmaceuticals Advances Regulatory Approvals and Clinical Trials for Neurological Drug